Patients with metastatic colorectal cancer whose tumors express wild-type KRAS are candidates for cetuximab treatment. Those with mutations in the BRAF gene may also respond poorly. For head and neck cancer, cetuximab can be used regardless of genetic testing results, though other factors such as overall health and cancer staging are considered.
